Tirofiban Preserves Endothelial Junctions and Decreases Endothelin-1
| Autor: | Run-Lin Gao, Jing-Lin Zhao, Ya-Xin Liu, Mei Zhai, Yue-Jin Yang, Yu-Hua Sun, Wei-Dong Pei |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
Study groups Endothelin-1 Myocardial tissue business.industry Pharmaceutical Science Acute myocardial infarction Tirofiban No-reflow Anterior Descending Coronary Artery medicine.disease Endothelin 1 Internal medicine Reperfusion Occlusion cardiovascular system medicine Cardiology cardiovascular diseases Myocardial infarction business medicine.drug |
| Zdroj: | Scientia Pharmaceutica Volume 76 Issue 2 Pages 171-184 |
| ISSN: | 0036-8709 |
| DOI: | 10.3797/scipharm.0803-21 |
| Popis: | It has been verified that glycoprotein IIb/IIIa inhibitor tirofiban can attenuate myocardial no-reflow. Myocardial no-reflow has been associated with alterations in endothelial junctions. In addition, ET-1 is an important mechanism for myocardial no-reflow. However, the effect of tirofiban on endothelial junctions and Endothelin-1 (ET-1) is unknown. Methods: Twenty-eight mini-swines were randomized into 3 study groups: 10 in control, 10 given an intravenous infusion of tirofiban and 8 in sham-operated. Acute myocardial infarction and reperfusion model was created with three-hour occlusion of the left anterior descending coronary artery followed by one-hour reperfusion. Results: In control group, plasma ET-1 significantly increased, ET-1 or VE-cadherin level in the reflow and no-reflow myocardium was significantly higher or lower than that in normal myocardium. Compared with the control group, tirofiban significantly decreased plasma ET-1 and myocardial tissue ET-1, maintained VE-cadherin level. Conclusions: Tirofiban is effective in preserving endothelial junction. This beneficial effect of tirofiban could be partly due to its reduction of ET-1. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|